Evidence map›Paper›PMID 37234988›Full record

ArticleFrontiers in oncology2023

The prognostic value of

Anqi Zheng, Zhuonan Wang, Liang Luo, Ruxi Chang, Jungang Gao, Bo Wang, Xiaoyi Duan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. To see clear is not enough; it is the action that counts.Translational andrology and urology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anqi ZhengPET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhuonan WangPET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Liang LuoPET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ruxi ChangPET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jungang GaoPET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Bo WangPET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xiaoyi DuanPET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate predictors for upgrading of newly diagnosed prostate cancer from systematic biopsy (SB) to radical prostatectomy (RP) using fluorine-18 prostate-specific membrane antigen 1007 ( Materials and methods: We retrospectively collected data from biopsy-confirmed prostate cancer (PCa) patients who underwent Results: Pathological upgrading occurred in 26.97% (41/152) PCa patients, and 23.03% (35/152) of all patients experienced pathological downgrading. Concordance rate reached 50% (76/152). International Society of Urological Pathology grade group (ISUP GG) 1(77.78%) and ISUP GG 2 (65.22%) biopsies were related with the highest rate of upgrading. Multivariable logistic regression analyses showed that prostate volume (OR= 0.933; 95% CI, 0.887-0.982; p = 0.008), ISUP GG 1 Conclusion:

Indexed as

18F-PSMA-1007 PET/CTbiopsyGleason grade groupprostate cancerradical prostatectomy

Identifiers

PMID37234988
PMCPMC10206242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.